Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.20    3.40 (2.23%)
Bid:
156.00
Ask:
156.40
Spread: 0.40 (0.256%)
Market Cap: £893.96m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM Trading Statement

30 Apr 2019 07:00

RNS Number : 4715X
Elementis PLC
30 April 2019
 

Elementis plc

AGM Trading Statement

Market conditions remain challenging, particularly in Coatings

On track to deliver further progress in 2019 led by self-help initiatives

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 March 2019.

Reflecting broader macroeconomic trends, global market conditions remain challenging, particularly in Coatings. Elementis anticipates further progress in 2019, albeit slightly below expectations. Some improvement in the demand environment and further cost efficiencies in-train are expected to result in a stronger second half performance.

The Group remains focused on delivering its plans to integrate the Talc business, transform Coatings and grow Personal Care. This strategy, supported by self-help measures focused on cost efficiency and cash delivery will provide a robust financial platform to deliver future growth and shareholder value creation.

Business performance

· Personal Care had a solid first quarter with strong growth in cosmetics offset by a weaker start in anti-perspirant active ingredients. Bentone HydroclayTM, our new hectorite-based ingredient focused on the skin care market, launched in the quarter and is building encouraging customer momentum.

 

· In Coatings, whilst price/mix improved, weak demand and some de-stocking, particularly in Asia, caused revenue to decline versus the strong prior year period. Early benefits of the transformation programme helped to partially mitigate the profit impact and the programme continues to progress at pace.

 

· Integration of the Talc business remains on track for completion by October 2019 with a focus on delivering $2m of identified cost synergies and new business opportunities. Against strong comparatives, the business saw robust performance across most of its industrial talc applications but weaker demand from paper and automotive markets.

 

· Energy had a steady start to the year with industry infrastructure constraints in North America anticipated to ease in H2.

 

· Chromium sales grew on the prior year period with improved pricing offsetting lower demand levels.

 

Commenting on the performance, CEO, Paul Waterman said,

"Whilst trading conditions in the first quarter of 2019 have proved challenging, Elementis remains focused on delivery, improving returns and deleveraging. This will be underpinned by the integration of the Talc business, delivery of self-help efficiency measures and an unrelenting focus on cash generation."

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson Tel: 020 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLLFFTSVIAFIA
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.